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Background. We report our experience with vinorelbine, a widely used chemotherapeutic, in unselected metastatic breast cancer
patients treated in clinical routine. Patients andMethods.The data of all patients with metastatic breast cancer receiving vinorelbine
with or without trastuzumab during a six year period were reviewed. Patients received vinorelbine intravenous 25–30mg/m2 or 60–
80mg/m2 orally in days 1 and 8 of a 21 day cycle.Results. Eighty-sevenwomenwere included. Sixty-two patients received vinorelbine
alone and 25 patients received vinorelbine in combination with trastuzumab. In 67 patients this was the first line treatment for
metastatic disease and in 20 patients it was 2nd or later line of treatment. The median TTP was six months (range: 1–45). The
median overall survival was 11.5 months (range: 1–83). Seventy patients were evaluable for response. In patients receiving first line
treatment 44.4% had a response while in the second and subsequent lines setting 12.5% of patients responded (𝑃 = 0.001). Objective
response was obtained in 63.6% of patients receiving concomitant trastuzumab and in 25% of patients receiving vinorelbine alone
(𝑃 = 0.0002).Conclusion.This study confirms a high disease control rate. Response rate andTTPwere superior in first line treatment
compared to subsequent lines.
1. Introduction
Breast carcinoma is the most common female cancer and
among the most frequent causes of cancer mortality in
women worldwide [1, 2]. Metastatic breast cancer is consid-
ered incurable with median survival estimates of about 2 to 3
years, but treatments with endocrine, cytotoxic, or targeted
therapies can improve or maintain the quality of life and
prolong survival.
Vinorelbine is one of the most widely used drugs in
metastatic breast cancer. With the increasing use of anthra-
cyclines and taxanes in the adjuvant setting there is a trend
on advancing other drugs such as vinorelbine and capeci-
tabine in earlier lines of treatment in the metastatic setting.
Vinorelbine belongs to the family of vinca alkaloids together
with vincristine, vinblastine, vindesine, and vinflunine [3].
All drugs of the vinca family share their mechanism of
action,metabolismby hepatic disposition, and adverse effects
profile. Vinorelbine differs from the older drugs of the family,
vincristine and vinblastine, in that it is semisynthetic and has
a higher affinity for tubulin and lipophilicity [3].
Progress in molecular biology has led to characterization
of molecular subtypes of breast cancer based on genomic
profiling. Surrogate clinically used subsets are characterized
by the expression of a few proteins such as estrogen (ER) and
progesterone (PR) receptors, EGFR family member protein
Her2/Neu (HER2), and the Ki67 antigen as a marker of pro-
liferation [4]. These markers can be reproducibly measured
by immunohistochemistry (and/or an in situ hybridization
method in the case of Her2) in clinical pathology laboratories
and have become a standard component of breast cancer eval-
uation to define prognosis and help in therapeutic decisions.
Breast cancer with HER2 protein overexpression or gene
amplification represents a subset for which prognosis has
been improved after the introduction of targeted therapies
that inhibit the receptor [5]. The first of these therapies was
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the humanized monoclonal antibody trastuzumab registered
more than 10 years ago. Trastuzumab has been shown to
improve treatment efficacy both in the adjuvant and in the
metastatic settings in combination with chemotherapy [5, 6].
Several chemotherapeutic drugs have been studied in HER2
overexpressing metastatic breast cancer in combination with
trastuzumab including vinorelbine. InHER2negative cancers
vinorelbine is frequently used as monotherapy.
In this retrospective study we report retrospectively the
experience of our center with vinorelbine (with or without
trastuzumab) in unselected metastatic breast cancer patients
in order to further define expectations in HER2 positive and
negative disease and in the first and subsequent lines.
2. Patients and Methods
Data of patients included in this study were retrieved from
our department patient archives containing the clinical data
of women who received treatment for metastatic breast
cancer. All patients with metastatic breast cancer receiving
vinorelbine with or without trastuzumab during a six year
period were retrospectively reviewed. Demographic data,
biologic characteristics of the tumor and data on response,
and time to progression (TTP) and overall survival (OS)
were collected. Patients were treated with vinorelbine IV 25–
30mg/m2 or PO 60–80mg/m2 in days 1 and 8 of a 21 day
cycle. Patients with HER2 3+ tumors by immunohistochem-
istry or positive by FISH (fluorescent in situ hybridization)
received trastuzumab in addition to vinorelbine while HER2
negative patients were treated with vinorelbinemonotherapy.
Patients who received vinorelbine in combination with other
chemotherapeutics and patients with incomplete follow-up
data were excluded. In patients that received concomitant
trastuzumab a standard intravenous dosing schedule with
8mg/kg loading dose followed by 6mg/kg in subsequent
administrations every three weeks was used.
Data collection and recording was conducted in compli-
ance with the ethical requirements of our center and patients’
anonymity was guaranteed. Due to the retrospective nature
of the analysis and the fact that treatments had been provided
according to standards of care, no specific informed consents
were obtained.
Tumor response was recorded according to the revised
RECIST (Response Evaluation Criteria in Solid Tumors)
criteria [7]. Response rate was defined as the addition of
complete response (CR) and partial response (PR). Disease
control rate (DCR) was defined as the response rate plus the
stable disease (SD) rate. TTP and OS were calculated by the
Kaplan-Meier method starting from the date of vinorelbine
therapy initiation to the date of disease progression docu-
mentation or death. Comparisons were made with the log
rank test. The 𝑥2 test was used to evaluate differences in clin-
ical and biologic characteristics in the different groups. A
Cox regression proportional hazard multivariate analysis
was performed to identify statistically significant factors
associated with TTP and OS. All 𝑃 values were considered
to be significant at the level of 𝑃 < 0.05. Statistical
calculations were performed using an online tool from Den-
mark Technical University, Informatics Statistical Consulting
Center (https://statcom.dk/K-M plot.php) and a noncom-
mercial statistical calculation site (http://www.statpages
.org/).
3. Results
From 2006 to 2012, a total of 87 patients were fulfilling the
criteria of the study. Baseline demographic and other cha-
racteristics of the included patients are presented in Table 1.
The median age was 63 years (range: 32–85). Sixty-two
patients received vinorelbine alone and 25 patients received
vinorelbine with trastuzumab. In 67 patients this was the first
line treatment for metastatic disease and in 20 patients it was
2nd or later line of treatment. Seventy patients were evaluable
for response, while the remaining seventeen patients were
not evaluable due to early progression (𝑛 = 6) or early
termination of treatment for adverse effects (𝑛 = 11).
The overall response rate in evaluable patients in the
cohort was 37.1% (1.4% complete response (CR) and 35.7%
partial response (PR)). Eighteen additional patients (25.7%)
had stable disease (SD) for at least three months resulting
in a DCR of 62.8%. Twenty-four out of 54 patients (44.4%)
receiving first line treatment obtained an objective response
while in the second and subsequent lines of setting two of
16 patients (12.5%) responded (𝑥2 = 9.66, 𝑃 = 0.001)
(Table 2). 95% confidence intervals of different response
groups are given in Table 2. DCR was 66.6% and 50% in
patients in first and second or later line treatment, respec-
tively. A response (CR or PR) was obtained in 63.6% of
patients receiving concomitant trastuzumab and in 25% of
patients receiving vinorelbine alone (𝑥2 = 13.63; 𝑃 = 0.0002)
(Table 3). DCR was 91% and 50% in patients receiving com-
bined vinorelbine-trastuzumab and vinorelbine monother-
apy, respectively.The response rate of patients with bone only
metastases at the time of vinorelbine treatment was 30% and
of patients with other sites of metastases (with or without
bones) was 40% (𝑃 = 0.43).
The median TTP was six months (range: 1–45). Sixty-six
patients of the cohort had died at the time of the analysis.
The median overall survival was 11.5 months (range: 1–83).
Seventy-three patients (83.9%) in the whole series had ER
and/or PR positive and 14 (16.1%) had ER/PR negative breast
cancer. Among evaluable for response patients, 60 (85.7%)
had ER and/or PR positive cancers and had a response rate
of 36.7% and 10 (14.3%) had ER/PR negative cancers and had
a response rate of 40%. From the 48 HER2 negative patients
who received vinorelbine alone only six were concomitantly
ER and PR negative (triple negative). Four of them had
PD, one SD and one PR. Adverse effects (mainly peripheral
neuropathy and GI symptoms) necessitating interruption of
treatment were observed in 18.5% of patients in the whole
cohort.
As expected both time to progression and overall survival
were shorter for patients receiving vinorelbine alone com-
paredwith vinorelbine combinedwith trastuzumab (Figures 1
and 2). Time to progression of patients receiving vinorelbine-
based treatment as first line metastatic therapy was also
significantly longer than for patients that received it as
second or later lines of therapy (Figure 3). Overall survival
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Table 1: Characteristics of all patients in this series and of the subset that was evaluable for response to vinorelbine treatment.
All patients 𝑛 = 87 (%) Evaluable for response patients 𝑛 = 70 (%)
Age, median [range] 63 [32–85] 61 [32–85]
OS median [range] 16 months [5–83] 11.5 months [1–83]
Follow-up (patients alive)
median [range] 13 months [3–50] 12 months [1–50]
Hormonal status
ER/PR positive 73 (83.9) 60 (85.7)
ER/PR negative 14 (16.1) 10 (14.3)
Treatment
Vinorelbine monotherapy 62 (71.3) 48 (68.6)
Vinorelbine + trastuzumab 25 (28.7) 22 (31.4)
Line of treatment
1st line 67 (77) 54 (77.1)
2nd or later 20 (23) 16 (22.9)
Table 2: Clinical response rates of patients with metastatic breast cancer treated with vinorelbine (with or without trastuzumab) either as 1st
or as later line of treatment.
1st line; 𝑛 = 54 (%) 95% CI (%) 2nd or later line; 𝑛 = 16 (%) 95% CI
CR 1 (1.9%) 0–10.7 0 0–22.7
PR 23 (42.6%) 30.3–55.9 2 (12.5%) 2.2–37.3
SD 12 (22.2%) 13.0–35.1 6 (37.5%) 18.4–61.5
PD 18 (33.3%) 22.2–46.7 8 (50%) 28.0–72.0
CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease, and 95% CI: 95% confidence interval.
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Figure 1: Kaplan-Meier curves of TTP for patients receiving
vinorelbine alone (𝑛 = 48) or vinorelbine plus trastuzumab (𝑛 = 22).
Log rank test 𝑃 = 0.0015.
did not differ significantly according to whether patients
received vinorelbine with or without trastuzumab as first
line metastatic treatment or second and later line treatment
(Figure 4).
Cox multivariate analysis showed that increasing age
and absence of trastuzumab association in the regimen
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Figure 2: Kaplan-Meier curves of OS for patients receiving vinorel-
bine alone (𝑛 = 48) or vinorelbine plus trastuzumab (𝑛 = 22). Log
rank test 𝑃 = 0.0081.
were statistically significantly associated with reduced overall
survival, while ER/PR status and metastases location at
the time of vinorelbine treatment (bone only versus other
locationswith orwithout bones) were not (Table 4). Similarly,
second or later line of treatment was not associated with
decreased OS, although approaching significance (𝑃 =
0.053). Regarding TTP, vinorelbine as second or later line of
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Table 3: Clinical response rates of patients withmetastatic breast cancer treated with vinorelbine either as monotherapy or with trastuzumab.
VNR mono; 𝑛 = 48 (%) 95% CI VNR + TRZ; 𝑛 = 22 (%) 95% CI
CR 0 0–8.8 1 (4.5%) 0–23.5
PR 12 (25%) 14.8–38.9 13 (59.1%) 38.7–76.8
SD 12 (25%) 14.8–38.9 6 (27.3%) 12.9–48.4
PD 25 (50%) 36.4–63.6 2 (9.1%) 1.3–29.0
CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease, VNR mono: vinorelbine monotherapy, VNR + TRZ: vinorelbine and
trastuzumab, and 95% CI: 95% confidence interval.
Table 4: Multivariate Cox regression model for possible factors influencing OS of patients with metastatic breast cancer. Age was included
as a continuous variable. ER/PR status was considered positive if either of the receptors was positive and negative if both were negative. Line
of treatment variable compares patients receiving vinorelbine containing treatment as first line metastatic therapy and those receiving it as
second or later line. Sites of metastases variable compares patients with bone metastases only and those with other sites also present (with or
without bones).
Variable Hazard ratio 95% confidence interval 𝑃 value
Lower limit Upper limit
Age 1.0275 1.0055 1.0499 0.014
ER/PR 1.1615 0.5982 2.2553 0.65
Trastuzumab 0.5032 0.2757 0.9183 0.025
Line of treatment 1.831 0.98 3.3891 0.053
Sites of metastases 1.1947 0.678 2.105 0.53
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Figure 3: Kaplan-Meier curves of TTP for patients receiving
vinorelbine with or without trastuzumab as 1st line metastatic
treatment (𝑛 = 54) versus as 2nd or later line (𝑛 = 16). Log rank
test 𝑃 = 0.015.
metastatic treatment and absence of trastuzumab association
in the regimen were statistically significantly associated with
shorter TTP, while age, ER/PR status, andmetastases location
at the time of vinorelbine treatment were not associated with
TTP (Table 5).
4. Discussion
Metastatic disease is one of the greatest challenges faced
by cancer specialists, partly because the variety of presenta-
tions, underlying biology, and increasing drug options make
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Figure 4: Kaplan-Meier curves of OS for patients receiving vinorel-
bine with or without trastuzumab as 1st line metastatic treatment
(𝑛 = 54) versus as 2nd or later line (𝑛 = 16). Log rank test 𝑃 = 0.14.
decisions regarding the optimal therapeutic approach com-
plicated. Both combinations of drugs and sequential single-
agent chemotherapy or endocrine therapy are reasonable
options as first line therapy depending on the specific situa-
tion [8]. One should bear in mind that metastatic breast can-
cer therapy is not given with a curative intent and conse-
quently respect of quality of life is one of the main goals of
treatment. On the other hand a rapid and significant response
to a treatment even with short term toxicities may be useful
and valuable in case of high burden cancer (i.e., extensive
visceral disease) [8].
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Table 5: Multivariate Cox regression model for possible factors influencing TTP of patients with metastatic breast cancer. Age was included
as a continuous variable. ER/PR status was considered positive if either of the receptors was positive and negative if both were negative. Line
of treatment variable compares patients who receive vinorelbine containing treatment as first line metastatic therapy and those receiving it as
second or later line. Sites of metastases variable compare patients with bone metastases only and those with other sites also present.
Variable Hazard ratio 95% confidence interval 𝑃 value
Lower limit Upper limit
Age 1.0052 0.9866 1.0242 0.58
ER/PR 0.7171 0.3815 1.3479 0.30
Trastuzumab 0.4372 0.2557 0.7475 0.002
Line of treatment 1.9358 1.1168 3.3554 0.018
Sites of metastases 1.3463 0.8052 2.2511 0.25
One of the cytotoxics that are commonly used in meta-
static breast cancer is vinorelbine [9, 10] particularly because
of its good tolerance profile. Vinorelbine is a semisynthetic
third generation vinca alkaloid that acts by inhibiting cancer
cell proliferation. Vinca alkaloids are chemically constituted
of a vindoline nucleus linked to a catharanthine moiety [3].
Theirmechanismof action consists of interferingwithmitotic
spindle progression during cell cycle and blocking it during
metaphase to anaphase transition. At higher concentrations,
they stimulate microtubule depolymerization and promote
mitotic spindle destruction. Their main molecular targets
are tubulin and microtubules. Vinorelbine, similarly to other
vinca alkaloids, binds to 𝛽-tubulin subunits at vinca-binding
domain near the positive end of microtubules. This is the
same binding site as that which binds alkaloid maytansine,
the cytotoxic component of the recently introduced com-
pound drug trastuzumab-DM. Taxanes and epipodophyl-
lotoxins bind to a different 𝛽-tubulin domain. Vinorelbine
binds rapidly and reversibly to soluble tubulin and induces a
conformational change that increases the affinity of tubulin
for itself. This change modulates the kinetics of micro-
tubule stabilization, reduces the rate ofmicrotubule dynamics
(lengthening and shortening), and increases the duration
which microtubules spend in an attenuated state. As a result
the tension at the kinetochores of chromosomes duringmito-
sis is reduced. Chromosomal condensation and separation
along their length are observed but chromosomes lurk at the
spindle poles and are unable to move properly towards the
spindle equator [3]. Interruption of spindle dynamics triggers
apoptosis that seems p53 independent [11]. Vinorelbine has
distinct clinical advantages over other vinca drugs such as
reduced peripheral neurotoxicity and oral availability. Its
greater lipophilicity increases its concentrations in certain
tissues such as lung compared with other drugs of the class
[3, 12].
Several trials and retrospective series have explored the
role of vinorelbine as monotherapy or with trastuzumab in
metastatic breast cancer and some examples will be outlined
below. In a phase III study of 252 anthracycline and taxanes
pretreated patients, vinorelbinemonotherapy was used as the
control arm and compared with vinorelbine combined with
gemcitabine [13]. The median PFS of the vinorelbine mono-
therapy arm was 4 months, the median OS was 16.4 months,
and the response rate was 26%. Although the PFS was
improved with the combination, the OS was not [13]. In a
phase II trial of vinorelbine in 50 anthracycline and taxane
pretreated patients the response rate was 20% and the TTP 115
days [14]. A recent small phase II study in patients previously
treated with taxanes and anthracyclines showed a response
rate to vinorelbine of 20.8% and a DCR of 58.3% [15]. The
median TTP and OS were 3.7 and 10.4 months. No difference
in response rate between the HER2 negative and HER2
positive patients, who did not receive trastuzumab in this
study, was observed [15]. In another phase II study of oral
vinorelbinemonotherapy in the first line setting that included
64 patients, the overall response rate was 31% [16]. Median
PFS was 17.4 weeks and median OS was not reached.
Responses observed with the combination of vinorelbine
and trastuzumab in HER2 positive patients are in general
higher than with monotherapy. A phase III trial that com-
pared vinorelbine/trastuzumab with docetaxel/trastuzumab
as later line treatment in HER2 positive patients pretreated
with anthracyclines and taxanes showed an identical response
rate of about 30% and 1 year survival of 88% in both arms
[17]. The vinorelbine arm showed a longer TTP (15.3 versus
12.4months) andwas better tolerated than the docetaxel arm.
In a phase II study of 42 patients that received vinorelbine
and trastuzumab in the first line setting RR was 70%, median
TTP was 9.3 months, and median OS was 35.6 months [18].
In another phase II study, patients had received no more
than one previous line of therapy and their response rate was
50%, while median TTP and OS were 9.6 and 22.7 months,
respectively [19]. A phase II trial in anthracycline and taxane
pretreated patients showed a response rate of 30.3% and
median TTP andOS of 6.8 and 12.4months, respectively [20].
In a retrospective series in the first line treatment ofHER2
positive disease, 67 patients treated with vinorelbine and
trastuzumab obtained a 57% response rate which was inferior
in this series to treatment with docetaxel and trastuzumab
(77%) [21]. In the salvage setting the response rate of 60HER2
positive patients treated with vinorelbine and trastuzumab
was 28% [22]. In another series of 100 patients treated with
oral vinorelbine with or without trastuzumab the response
rate was 25% and the disease control rate 51% [23]. The
response rate in first line and with trastuzumab was higher
in a way similar to our patients. In a study of 68 patients
with breast cancer, mostly (about 80%) treated in second or
later line, 33 received vinorelbine alone and had an ORR of
27.3% and 35 received vinorelbine plus trastuzumab and had
an ORR of 51.4% [24]. The TTP was 6 and 9 months and
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the OS 22 and 27 months, respectively. In a smaller series
of 30 patients with HER2 positive metastatic breast cancer
treated with oral vinorelbine (60mg without escalation) and
trastuzumab, the CR was 18%, PR 50%, and SD for more than
6 months 21% [25]. TTP was 9 months and both response
rates and TTP were influenced by whether treatment was
received as first or later line.
Our retrospective analysis confirms that vinorelbine-
based therapy is a valid first line and salvage option for
patients with metastatic breast cancer, in clinical situations
where monotherapy is preferred. Vinorelbine effectiveness
appears not to be modified by endocrine sensitivity of the
tumor or metastases location. Nevertheless, as other ther-
apies, this cytotoxic is less effective in patients who were
pretreated with one or more lines of therapy for metastatic
disease and better therapies are needed for these patients.
The activity of trastuzumab combined with chemotherapy
in HER2 overexpressing breast cancer has been documented
andwe have observed in the current cohort that the combina-
tion is highly effective in terms of TTP and OS. Introduction
of alternative targeted therapies for HER2 negative patients
to combine with vinorelbine or other chemotherapeutics
that would improve efficacy without increasing toxicity is an
urgent goal.
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